| Factor Information | |
|---|---|
| Data ID | 1345 |
| Factor | ICU stay |
| Description | ICU stays for the HTK group were significantly shorter than those of the St group (10.41±1.36 vs 20.46±3.63 days, P=0.002). |
| Biomarker | NA |
| Classification | A12 (clinical factor - treatment) |
| Association | |
|---|---|
| Application | treatment and prognosis |
| Objective | The purpose of this study was to compare myocardial protection of HTK and St. Thomas’ crystalloid cardioplegic solution in high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease. |
| p Value | 0.002 |
| Conclusion | HTK solution seems to be an effective and safe alternative to St. Thomas’ solution for cardioplegic reperfusion in high-risk patients with complex congenital heart disease. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 521 |
| CHD Type | isolated CHD |
| CHD Subtype | D-TGA/VSD/CHD with PAH |
| Reference | |
|---|---|
| PMID | 27191607 |
| Year | 2016 |
| Title | Histidine-tryptophan-ketoglutarate solution decreases mortality and morbidity in high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease: an 11-year experience from a single institution. |
| Sample | ||
|---|---|---|
| Population | Infants | |
| Source | Data | |
| Region | Beijing, China | |
| Method | Univariate and multivariate analysis | |
| Race | Asian | |
| Disease History | N/A | |
| Treatment History | arterial switch operation | |
| Group | histidine-tryptophan-ketoglutarate (HTK) group: myocardial protection was carried out with one single perfusion of HTK solution(Treatment) | St group: control group, myocardial protection with conventional St. Thomas’ cold potassium crystalloid cardioplegic solution(Control) |
| Number | 75 | 26 |
| Age | 3.4±0.4 years | 1.9±0.4 years |
| Gender (Male: Female) | 38:37 | 16:10 |
| Marker Level | 10.41±1.36 days | 20.46±3.63 days |
